Trial Profile
A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jan 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 451
- Sponsors Bristol-Myers Squibb
- 20 Sep 2021 Planned End Date changed from 13 Feb 2021 to 28 Oct 2021.
- 11 Mar 2021 Status changed from active, no longer recruiting to completed.
- 08 Mar 2021 Results published in the Journal of Clinical Oncology.